Indications of intravitreal avastin (bevacizumab)

Bevacizumab is a highly specific, recombinant, humanized monoclonal (IgG1) antibody

that selectively binds to and neutralizes the biologic activity of human vascular

endothelial growth factor (VEGF) approved by

FDA ( label approved on 07/31/2009 for AVASTIN, BLA no. 125085 ) for

1 Metastatic Colorectal Cancer

2 Non-Squamous Non−Small Cell Lung Cancer

3 Metastatic Breast Cancer

4 Glioblastoma

5 Metastatic Renal Cell Carcinoma.

Intravitreal bevacizumab has been used in eye for (ocular indications)

1 -Macular oedema due to –

central retinal vein occlusion,

branch retinal vein occlusion

diabetic retinopathy,

uveitis

2- neovascularisation –

Neovascular glaucoma

Proliferative diabetic retinopathy

Wet AMD

Retinopathy of prematurity